Autoimmune diseases, immune modulation, inflammation, and self-tolerance
221 articoli
Researchers identify OGFRL1 gene deficiency as a novel cause of chronic bone disease, with promising treatment response to TNF inhibitors.
New clinical insights into treating Rowell syndrome, a rare skin manifestation affecting lupus patients with serious complications.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
Systematic review reveals younger RA patients achieve higher remission rates and better outcomes with biologic therapies than older patients.
Real-world study reveals sarilumab and JAK inhibitors work equally well for rheumatoid arthritis, but sarilumab causes fewer infections.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
New research reveals how RA affects muscle biomechanics within 6 months of symptom onset, offering insights for early intervention.
Large Hong Kong registry study tracked how well patients stayed on newer JAK inhibitors versus traditional TNF blockers for RA treatment.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
Revolutionary cancer treatment adapted for autoimmune diseases achieves drug-free remission in lupus trials, with RA applications emerging.
Researchers outline the scientific roadmap needed to cure autoimmunity without lifelong immunosuppressive drugs.
